Biotechnology company CSL reported a half-year net profit after tax and amortisation of US$1.9 billion ($2.91 billion), showing a 13% increase yearly.

Immunoglobulin sales primarily led to a higher net profit. Revenue for the period reached US$8.05 billion ($12.34 billion), up 11%.

CSL's board declared an interim dividend of US$1.19 ($1.82) per share.

The company's FY24 net profit outlook is approximately US$2.9 billion ($4.44 billion) to US$3 billion ($4.60 billion), representing a growth of 13% to 17% over FY23.